{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:00:06Z","timestamp":1788865206335,"version":"build-2803163510"},"reference-count":42,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T00:00:00Z","timestamp":1588032000000},"content-version":"unspecified","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000884","name":"Cancer Research Institute","doi-asserted-by":"publisher","award":["CLIP Award"],"award-info":[{"award-number":["CLIP Award"]}],"id":[{"id":"10.13039\/100000884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32CA163177-08"],"award-info":[{"award-number":["5T32CA163177-08"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,3,30]]},"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Immunogenicity of cancer vaccines is impacted by adjuvants and schedule, but systematic assessments of their effects have not been performed. Montanide ISA-51, an incomplete Freund\u2019s adjuvant (IFA), is used in many vaccine trials, but concerns have been raised about negative effects in murine studies. We found in humans that IFA enhances systemic immune responses and that repeat vaccination at one site (same site vaccination (SSV)) creates tertiary lymphoid structures (TLS) in the vaccine site microenvironment (VSME). We hypothesized that vaccination with peptides+IFA+pICLC or SSV\u00d73 with peptides in IFA would create an immunogenic milieu locally at the VSME, with activated dendritic cells (DC), TLS-associated chemokines and a Th1-dominant VSME.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Biopsies of the VSME were obtained from participants on two clinical trials who were immunized with multiple melanoma peptides (MELITAC 12.1) in adjuvants comprising IFA and\/or the TLR3-agonist pICLC. Biopsies were obtained either a week after one vaccine or a week after SSV\u00d73. Controls included normal skin and skin injected with IFA without peptides. Gene expression analysis was performed by RNAseq.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>VSME samples were evaluated from 27 patients. One vaccine with peptides in pICLC+IFA enhanced expression of CD80, CD83, CD86 (p&lt;0.01), CD40 and CD40L (p&lt;0.0001) over normal skin; these effects were significantly enhanced for SSV with peptides+IFA. Vaccines containing pICLC increased expression of TBX21 (T-bet) but did not decrease GATA3 over normal skin, whereas SSV with peptides in IFA dramatically enhanced TBX21 and decreased GATA3, with high expression of IFN\u03b3 and STAT1. SSV with peptides in IFA also reduced arginase-1 (ARG1) expression and enhanced expression of TLR adapter molecules TICAM-1 (TRIF) and MYD88. Furthermore, SSV with IFA and peptides also enhanced expression of chemokines associated with TLS formation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These findings suggest that SSV with peptides in IFA enhances CD40L expression by CD4 T cells, supports a Th1 microenvironment, with accumulation of activated and mature DC. Increased expression of TLR adaptor proteins after SSV with peptides in IFA might implicate effects of the skin microbiome. Reduced ARG1 may reflect diminished suppressive myeloid activity in the VSME.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>(<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00705640\">NCT00705640<\/jats:ext-link>, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01585350\">NCT01585350<\/jats:ext-link>).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2020-000544","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T03:56:46Z","timestamp":1588132606000},"page":"e000544","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":28,"title":["Incomplete Freund\u2019s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct00705640","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01585350","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02425306","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Karlyn E","family":"Pollack","sequence":"first","affiliation":[{"name":"Surgery, University of Virginia, Charlottesville, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8410-061X","authenticated-orcid":false,"given":"Max O","family":"Meneveau","sequence":"additional","affiliation":[{"name":"Surgery, University of Virginia, Charlottesville, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marit M","family":"Melssen","sequence":"additional","affiliation":[{"name":"Surgery, University of Virginia, Charlottesville, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin T","family":"Lynch","sequence":"additional","affiliation":[{"name":"Surgery, University of Virginia, Charlottesville, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander F","family":"Koeppel","sequence":"additional","affiliation":[{"name":"Biology, University of Virginia, Charlottesville, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel J","family":"Young","sequence":"additional","affiliation":[{"name":"Office of Research Cores Administration (ORCA), University of Virginia School of Medicine, Charlottesville, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Turner","sequence":"additional","affiliation":[{"name":"Public Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Kumar","sequence":"additional","affiliation":[{"name":"Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Sol-Church","sequence":"additional","affiliation":[{"name":"Pathology, University of Virginia School of Medicine, Charlottesville, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana S","family":"Mauldin","sequence":"additional","affiliation":[{"name":"Surgery, University of Virginia, Charlottesville, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig L","family":"Slingluff Jr","sequence":"additional","affiliation":[{"name":"Surgery, University of Virginia, Charlottesville, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,4,28]]},"reference":[{"key":"2025100308413025000_8.1.e000544.1","doi-asserted-by":"crossref","first-page":"C25","DOI":"10.1016\/j.vaccine.2010.07.021","article-title":"Unmet needs in modern vaccinology: adjuvants to improve the immune response","volume":"28 Suppl 3","author":"Leroux-Roels","year":"2010","journal-title":"Vaccine"},{"key":"2025100308413025000_8.1.e000544.2","doi-asserted-by":"publisher","DOI":"10.1093\/ilar.46.3.280"},{"key":"2025100308413025000_8.1.e000544.3","doi-asserted-by":"publisher","DOI":"10.1126\/science.101.2627.468-a"},{"key":"2025100308413025000_8.1.e000544.4","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-011-9632-5"},{"key":"2025100308413025000_8.1.e000544.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.08.031"},{"key":"2025100308413025000_8.1.e000544.6","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1016\/j.vaccine.2012.04.089","article-title":"Synthetic influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled phase I trial","volume":"30","author":"Pleguezuelos","year":"2012","journal-title":"Vaccine"},{"key":"2025100308413025000_8.1.e000544.7","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00098-15"},{"key":"2025100308413025000_8.1.e000544.8","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-017-2341-9","article-title":"Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by seek: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial","volume":"17","author":"van Doorn","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2025100308413025000_8.1.e000544.9","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2013.811188"},{"key":"2025100308413025000_8.1.e000544.10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1544"},{"key":"2025100308413025000_8.1.e000544.11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.8053"},{"key":"2025100308413025000_8.1.e000544.12","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.9.6169"},{"key":"2025100308413025000_8.1.e000544.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810097"},{"key":"2025100308413025000_8.1.e000544.14","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3105"},{"key":"2025100308413025000_8.1.e000544.15","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0625-x"},{"key":"2025100308413025000_8.1.e000544.16","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/CJI.0b013e31823731a4","article-title":"The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides","volume":"35","author":"Harris","year":"2012","journal-title":"J Immunother"},{"key":"2025100308413025000_8.1.e000544.17","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-8-79"},{"key":"2025100308413025000_8.1.e000544.18","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1435-5"},{"key":"2025100308413025000_8.1.e000544.19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0486"},{"key":"2025100308413025000_8.1.e000544.20","doi-asserted-by":"publisher","DOI":"10.1084\/jem.180.4.1263"},{"key":"2025100308413025000_8.1.e000544.21","doi-asserted-by":"publisher","DOI":"10.1084\/jem.184.2.747"},{"key":"2025100308413025000_8.1.e000544.22","doi-asserted-by":"crossref","unstructured":"Messina JL , Fenstermacher DA , Eschrich S , et al . 12-Chemokine gene signature identifies lymph Node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep 2012;2.doi:10.1038\/srep00765","DOI":"10.1038\/srep00765"},{"key":"2025100308413025000_8.1.e000544.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209217"},{"key":"2025100308413025000_8.1.e000544.24","first-page":"3012","article-title":"Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes","volume":"7","author":"Slingluff","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2025100308413025000_8.1.e000544.25","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.4197"},{"key":"2025100308413025000_8.1.e000544.26","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.12688\/f1000research.7563.1","article-title":"Differential analyses for RNA-Seq: transcript-level estimates improve gene-level inferences","volume":"4","author":"Soneson","year":"2015","journal-title":"F1000Res"},{"key":"2025100308413025000_8.1.e000544.27","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2010-11-10-r106"},{"key":"2025100308413025000_8.1.e000544.28","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8"},{"key":"2025100308413025000_8.1.e000544.29","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-10-161"},{"key":"2025100308413025000_8.1.e000544.30","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkt1076"},{"key":"2025100308413025000_8.1.e000544.31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506580102"},{"key":"2025100308413025000_8.1.e000544.32","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031591"},{"key":"2025100308413025000_8.1.e000544.33","doi-asserted-by":"publisher","DOI":"10.4161\/hv.29847"},{"key":"2025100308413025000_8.1.e000544.34","doi-asserted-by":"publisher","DOI":"10.1038\/srep00765"},{"key":"2025100308413025000_8.1.e000544.35","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.3.1564"},{"key":"2025100308413025000_8.1.e000544.36","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0833"},{"key":"2025100308413025000_8.1.e000544.37","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-7-93","article-title":"Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous Toll-like receptor 9 stimulation","volume":"7","author":"Carpenter","year":"2009","journal-title":"J Transl Med"},{"key":"2025100308413025000_8.1.e000544.38","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031591"},{"key":"2025100308413025000_8.1.e000544.39","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200523373"},{"key":"2025100308413025000_8.1.e000544.40","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3105"},{"key":"2025100308413025000_8.1.e000544.41","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200425830"},{"key":"2025100308413025000_8.1.e000544.42","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600883"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-000544","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T15:41:41Z","timestamp":1759506101000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-000544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,4,28]]},"published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1136\/jitc-2020-000544"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-000544","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}